28 citations
,
September 2021 in “JAAD Case Reports” This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.
9 citations
,
January 2023 in “Journal of Cutaneous Immunology and Allergy” This case report describes a 37-year-old woman who developed widespread hair loss following the BNT162b2 mRNA vaccine, which mostly recovered after topical corticosteroid treatment.
8 citations
,
July 2024 in “European journal of medical research” This study reported that alopecia areata following COVID-19 vaccination is rare, occurring mostly after the first dose and associated with several vaccine types, particularly Pfizer.
2 citations
,
February 2023 in “Vaccines” This study reported cases of post-vaccine telogen effluvium and alopecia among five individuals in Ecuador following a mixed COVID-19 vaccination regimen, typically appearing within 3 to 17 days after inoculation.
May 2022 in “International Journal of Dermatology” This report describes a case of alopecia areata presenting as Marie Antoinette syndrome shortly after Pfizer/BioNTech COVID-19 vaccination, with hair regrowth and partial repigmentation following treatment.